Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423489 | 0.94 | MEN1 (0.54) | MEN1KMT2AL3MBTL1STAT3MAPK10 | |
| SCHEMBL3418586 | 0.91 | MEN1 (0.59) | MEN1KMT2AL3MBTL1STAT3MAPK10 | |
| SCHEMBL3419561 | 0.88 | MEN1 (0.51) | MEN1KMT2AL3MBTL1STAT3GRM1 | |
| SCHEMBL3434519 | 0.87 | MEN1 (0.61) | MEN1KMT2AL3MBTL1STAT3GRM1 | |
| SCHEMBL3419027 | 0.87 | L3MBTL1 (0.60) | MEN1KMT2AL3MBTL1STAT3 | |
| SCHEMBL3423278 | 0.87 | MEN1 (0.52) | MEN1KMT2AL3MBTL1STAT3GRM1 | |
| SCHEMBL3419906 | 0.87 | MEN1 (0.52) | MEN1KMT2AL3MBTL1STAT3GRM1 | |
| SCHEMBL3419082 | 0.87 | MEN1 (0.49) | MEN1KMT2AL3MBTL1STAT3MAPK10 | |
| SCHEMBL3421298 | 0.87 | MEN1 (0.66) | MEN1KMT2AL3MBTL1GRM1CRHBP | |
| SCHEMBL3423218 | 0.86 | MEN1 (0.53) | MEN1KMT2AL3MBTL1STAT3GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | claimed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | claimed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | claimed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | claimed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | MEN1 4691/4885KMT2A 2644/4885L3MBTL1 2416/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | MEN1 4735/4885KMT2A 2418/4885L3MBTL1 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.